^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    IASLC-WCLC 2020
    Title:

    P37.05 - Prognostic Characteristics and Immunotherapy Response of Non-Squamous NSCLC Patients with KRAS Mutation in East Asian Populations

    Published date:
    01/12/2021
    Excerpt:
    Among 5278 non-squamous NSCLC patients...About the treatment response of immune checkpoint inhibitors (ICIs), patients with Kras-G12C had a higher response rate (50% vs. 14.3%; p = 0.069) and longer progression-free survival (4.8 mo vs. 2.1 mo; p = 0.046) than those with Kras-non-G12C.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    JTO Clin Res Rep
    Title:

    Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan

    Published date:
    12/26/2020
    Excerpt:
    This study aimed to analyze the clinical characteristics, immune checkpoint inhibitor (ICI) response, and prognostic factors of patients with NSCLC with different Kras mutation subtypes....Among the 25 patients treated with ICIs, patients with Kras-G12C had a higher response rate (53.8% versus 8.3%, p = 0.030) and longer progression-free survival (4.8 mo versus 2.1 mo, p = 0.028) than those with Kras-non-G12C.
    DOI:
    10.1016/j.jtocrr.2020.100140